A detailed history of Bank Of America Corp transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Bank Of America Corp holds 32,140 shares of VRCA stock, worth $255,513. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,140
Previous 29,152 10.25%
Holding current value
$255,513
Previous $212,000 20.28%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.95 - $7.95 $23,754 - $23,754
2,988 Added 10.25%
32,140 $255,000
Q2 2024

Aug 14, 2024

BUY
$5.89 - $9.56 $12,857 - $20,869
2,183 Added 8.09%
29,152 $212,000
Q1 2024

May 15, 2024

SELL
$4.74 - $6.81 $46,034 - $66,138
-9,712 Reduced 26.48%
26,969 $159,000
Q4 2023

Feb 14, 2024

SELL
$2.93 - $7.32 $21,884 - $54,673
-7,469 Reduced 16.92%
36,681 $268,000
Q2 2023

Aug 14, 2023

BUY
$5.32 - $6.79 $35,681 - $45,540
6,707 Added 17.91%
44,150 $254,000
Q1 2023

May 12, 2023

BUY
$2.88 - $8.51 $49,245 - $145,512
17,099 Added 84.05%
37,443 $243,000
Q4 2022

Feb 10, 2023

BUY
$2.09 - $3.39 $1,316 - $2,135
630 Added 3.2%
20,344 $55,000
Q3 2022

Nov 14, 2022

SELL
$2.17 - $4.3 $352,006 - $697,524
-162,215 Reduced 89.16%
19,714 $57,000
Q2 2022

Aug 12, 2022

BUY
$1.81 - $8.93 $228,132 - $1.13 Million
126,040 Added 225.52%
181,929 $349,000
Q1 2022

May 16, 2022

BUY
$7.59 - $9.49 $208,254 - $260,386
27,438 Added 96.44%
55,889 $454,000
Q4 2021

Feb 08, 2022

BUY
$9.1 - $13.36 $167,376 - $245,730
18,393 Added 182.87%
28,451 $260,000
Q3 2021

Nov 15, 2021

SELL
$9.55 - $13.96 $12,644 - $18,483
-1,324 Reduced 11.63%
10,058 $125,000
Q2 2021

Sep 13, 2021

BUY
$9.77 - $15.33 $111,202 - $174,486
11,382 New
11,382 $128,000

Others Institutions Holding VRCA

About Verrica Pharmaceuticals Inc.


  • Ticker VRCA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,094,100
  • Market Cap $327M
  • Description
  • Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...
More about VRCA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.